Pietragallo Gordon Alfano Bosick & Raspanti partners William Pietragallo II and Eric G. Soller have stepped in to represent Viatris, a drug company formed through the 2020 merger of Mylan and Pfizer's Upjohn business, and its top officers in a pending securities class action. The action, filed June 15 in Pennsylvania Western District Court by Pomerantz LLP and attorney Anthony F. Jeselnik, accuses the defendants of failing to disclose that the company was experiencing more competition in its United States complex generics business; was not able to create a stable revenue base; and was actively planning to divest its biosimilars business. The case, assigned to U.S. District Judge Marilyn J. Horan, is 2:23-cv-01098, Mccord v. Viatris Inc. et al.
Biotech & Pharmaceuticals
June 29, 2023, 7:40 AM